DCT

1:26-cv-00324

Onyx Therap Inc v. Hetero USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00324, D. Del., 03/24/2026
  • Venue Allegations: Venue is alleged to be proper for Defendant Hetero USA as it is incorporated in Delaware. Venue is alleged to be proper for the foreign defendants, Hetero Labs and Hetero Limited, as they may be sued in any judicial district where personal jurisdiction exists.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's KYPROLIS® (carfilzomib) product constitutes an act of infringement of a patent covering a stable, injectable formulation of the drug.
  • Technical Context: The technology relates to pharmaceutical compositions that increase the solubility and stability of peptide-based proteasome inhibitors, a class of drugs used to treat cancers like multiple myeloma.
  • Key Procedural History: The complaint notes that in a prior litigation (C.A. No. 16-988-LPS), the U.S. District Court for the District of Delaware found Claim 31 of the patent-in-suit to be not invalid, a decision affirmed by the U.S. Court of Appeals for the Federal Circuit. This history may create a significant procedural hurdle for Defendants regarding invalidity challenges to that specific claim.

Case Timeline

Date Event
2004-12-07 U.S. Patent No. 7,737,112 Priority Date
2010-06-15 U.S. Patent No. 7,737,112 Issues
2011-01-01 FDA grants KYPROLIS® "Fast Track" designation (approx. date)
2012-07-20 FDA grants accelerated approval for Onyx's KYPROLIS®
2019-05-01 Prior litigation bench trial begins (approx. date)
2020-05-04 D. Del. finds Claim 31 of the '112 Patent not invalid
2021-03-08 Federal Circuit affirms D. Del. decision on '112 Patent
2026-02-09 Date of Hetero's Notice Letter regarding ANDA No. 220609
2026-03-24 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,737,112 - "Composition For Enzyme Inhibition"

  • Patent Identification: U.S. Patent No. 7,737,112 ("the '112 Patent"), "Composition For Enzyme Inhibition," issued June 15, 2010.

The Invention Explained

  • Problem Addressed: The patent addresses the low aqueous solubility of certain potent peptide epoxy ketone proteasome inhibitors, which makes it difficult to formulate them into compositions suitable for administration to patients, particularly for intravenous use '112 Patent, col. 1:25-28
  • The Patented Solution: The invention claims to solve this problem by combining the "practically insoluble" proteasome inhibitor with a cyclodextrin, specifically a substituted β-cyclodextrin such as sulfobutylether beta-cyclodextrin (SBECD) '112 Patent, abstract '112 Patent, col. 1:31-36 This combination significantly enhances the inhibitor's solubility '112 Patent, abstract The patent further describes that including a buffer to control the pH of the resulting solution provides an "optimal balance of solubility and stability" '112 Patent, col. 2:49-53 The relationship between pH, solubility, and stability is illustrated in the patent's figures '112 Patent, Fig. 1 '112 Patent, Fig. 2
  • Technical Importance: This formulation technology was critical for transforming a potent but difficult-to-administer chemical compound into a viable, stable, and effective injectable drug for treating serious diseases like cancer '112 Patent, col. 1:15-19

Key Claims at a Glance

  • The complaint asserts independent claims 1, 29, and 31, as well as dependent claims 2-9, 14, 18-24, and 30 '112 Patent, claim 1 '112 Patent, claim 29 '112 Patent, claim 31 Compl. ¶43
  • Independent Claim 1 requires:
    • A pharmaceutical composition
    • comprising a practically insoluble peptide epoxy ketone proteasome inhibitor
    • and a substituted cyclodextrin selected from hydroxypropyl beta-cyclodextrin and sulfobutylether beta-cyclodextrin (SBECD)
  • Independent Claim 29 requires:
    • A pharmaceutical composition
    • comprising a compound with the specific chemical structure of carfilzomib
    • and a substituted cyclodextrin selected from hydroxypropyl beta-cyclodextrin and SBECD
  • Independent Claim 31 requires:
    • A pharmaceutical composition
    • comprising a compound with the specific chemical structure of carfilzomib
    • in an aqueous solution
    • containing 10% (w/v) SBECD and 10 mM citric acid
    • adjusted to pH 3.5

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendants' "Proposed ANDA Product," the subject of Abbreviated New Drug Application (ANDA) No. 220609, which is a proposed generic version of Onyx's KYPROLIS® (carfilzomib) for injection Compl. ¶6 Compl. ¶8

Functionality and Market Context

The complaint alleges the Proposed ANDA Product contains the active ingredient carfilzomib, which is a proteasome inhibitor used to treat multiple myeloma Compl. ¶37 The product is a lyophilized powder that, according to the complaint, contains carfilzomib, sulfobutylether beta-cyclodextrin (SBECD), and citric acid Compl. ¶43 The proposed product label will allegedly instruct healthcare providers to reconstitute the powder into an aqueous solution for intravenous injection, thereby creating the allegedly infringing composition Compl. ¶39 Compl. ¶40 The filing of the ANDA itself represents a commercially significant challenge to the market exclusivity of KYPROLIS®, a drug noted for its effectiveness in treating multiple myeloma Compl. ¶20 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that Hetero's Proposed ANDA Product is covered by at least Claim 31 of the '112 Patent because it contains carfilzomib, SBECD, and citric acid Compl. ¶43 The proposed label instructions for reconstitution and administration are alleged to result in a composition that meets all limitations of the claim Compl. ¶39 Compl. ¶40

'112 Patent Infringement Allegations

Claim Element (from Independent Claim 31) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising a compound having a structure [of carfilzomib] The complaint alleges the Proposed ANDA Product contains carfilzomib as its active ingredient Compl. ¶37 ¶37; ¶43 col. 25:25-45
or a pharmaceutically acceptable salt thereof, The complaint does not provide sufficient detail for analysis of this specific element, but this is an alternative to the base compound. col. 38:63-65
in an aqueous solution The proposed product label allegedly instructs users to reconstitute the lyophilized powder with "Sterile Water for Injection, USP" before administration Compl. ¶39 ¶39 col. 42:26-27
containing 10% (w/v) SBECD The complaint alleges the Proposed ANDA Product contains sulfobutylether beta-cyclodextrin (SBECD) Compl. ¶43 ¶43 col. 3:9-10
and 10 mM citric acid The complaint alleges the Proposed ANDA Product contains citric acid Compl. ¶43 ¶43 col. 2:57-58
adjusted to pH 3.5. The FDA-approved label for KYPROLIS®, which the proposed generic label allegedly copies, specifies a target pH of 3.5 Compl. ¶22 Compl. ¶39 ¶22; ¶39 col. 3:23-24
  • Identified Points of Contention:
    • Validity Questions: A primary point of contention, as is common in ANDA litigation, will likely concern the validity of the asserted patent claims. The complaint preemptively notes that Claim 31 was previously upheld as not invalid Compl. ¶28, which raises the question of what new arguments or evidence Defendants could introduce to challenge that specific claim, or the other asserted claims not subject to the prior ruling.
    • Compositional Questions: While infringement is often stipulated in ANDA cases based on the generic's bioequivalence to the branded product, a potential question for the court is whether the Defendants' Proposed ANDA Product, as described in its FDA filing, will in fact contain every claimed element at the specified concentrations and pH upon reconstitution as instructed by its proposed label.

V. Key Claim Terms for Construction

  • The Term: "practically insoluble"

  • Context and Importance: This term appears in independent Claim 1 and defines the scope of the active ingredients covered by the broadest claim. The degree of insolubility is a fundamental characteristic of the problem the patent purports to solve, making its definition critical to determining the claim's boundaries.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent does not limit the term to specific compounds, suggesting it applies to any "peptide epoxy ketone proteasome inhibitor" that meets the functional definition of insolubility.
    • Evidence for a Narrower Interpretation: The specification provides a definition: "proteasome inhibitors that generally have a solubility of less than 0.1 mg/mL in water" '112 Patent, col. 34:34-37 Parties may dispute whether this creates a bright-line rule or is merely an exemplary guide.

  • The Term: "adjusted to pH 3.5"

  • Context and Importance: This limitation in Claim 31 is highly specific and was central to the previously litigated claim. Its construction will determine whether any minor deviation in the pH of the accused product avoids infringement. Practitioners may focus on this term because the patent specification discusses pH in terms of ranges and optimality, while the claim recites a precise value.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The detailed description discusses pH ranges, such as "from pH 2.5 to pH 9" and gives an example of a formulation with "a pH of about pH 3 to about pH 6" '112 Patent, col. 2:43-44 '112 Patent, col. 3:21-22 This could support an argument that "3.5" should encompass minor variations consistent with standard pharmaceutical practice.
    • Evidence for a Narrower Interpretation: The claim language itself recites the number "3.5" without modifiers like "about." Figure 1 of the patent shows a steep solubility curve around pH 3.5, which a party could use to argue that this exact pH is a critical, deliberately chosen value essential to the invention, not a general target '112 Patent, Fig. 1

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement, stating that Defendants' proposed product label will contain instructions that "will induce healthcare providers to use the Proposed ANDA Product in a manner set forth in those instructions" that infringes the '112 Patent Compl. ¶39 Knowledge is alleged based on Defendants' awareness of the patent at the time of the ANDA filing Compl. ¶31 Compl. ¶48
  • Willful Infringement: The complaint alleges that Defendants were aware of the '112 Patent when filing their ANDA and are "knowingly and intentionally infringing" Compl. ¶31 Compl. ¶50 It further alleges that Defendants "lacked a good-faith basis for alleging invalidity" when filing their Paragraph IV Certification, particularly in light of the prior litigation upholding Claim 31's validity, and asserts that the case is "exceptional" under 35 U.S.C. § 285 Compl. ¶28 Compl. ¶52

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of collateral estoppel and validity: given the prior Federal Circuit affirmance that Claim 31 is not invalid, a key threshold question is whether Defendants can present invalidity arguments against the remaining asserted claims (or even against Claim 31 itself) that are sufficiently new and material to overcome the preclusive effect of the earlier judgment.
  • A second core issue will be one of compositional identity: assuming the asserted claims are valid, a key evidentiary question is whether the chemical composition of Defendants' Proposed ANDA Product, as detailed in its FDA submission and intended to be manufactured and sold, will meet every limitation of the asserted claims upon reconstitution, including the specific active ingredient, excipients, and pH values claimed in the patent.
Loading Complaint